Company intelligence / Profile preview

Portola Pharmaceuticals

South San Francisco, California, United Statesportola.com ↗

Overview

Portola developed two FDA-approved drugs:

Andexxa® [coagulation factor Xa (recombinant), inactivated], the first antidote for patients treated with rivaroxaban or apixaban who require urgent reversal of anticoagulation due to life-threatening or uncontrolled bleeding.
Bevyxxa® (betrixaban), an oral Factor Xa inhibitor for prevention of VTE in acutely ill medical patients.
Cerdulatinib was in clinical development for hematologic cancers at time of acquisition. The company was acquired by Alexion Pharmaceuticals in July 2020

Therapeutic areas: OncologyHematologyCardiovascular
Modalities: small moleculesrecombinant proteins (e.g., coagulation factor Xa)monoclonal antibodies
Industry: Biotech

Novartis (past collaboration on Elinogrel)Millennium Pharmaceuticals, Daiichi Sankyo, Bayer, Janssen, BMS/Pfizer among others

Beyond the preview

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Follow clinical development from trial design and recruitment through results.

Explore licensing agreements, acquisitions, and the assets behind each deal.

Trace financing activity and the investors behind a company’s development.

Compare peer pipelines by target, modality, and therapeutic area.

Explore technology platforms and the patent landscape around relevant assets.

Connect company news and source material to the questions you’re investigating.

See how Gosset can support your research on Portola Pharmaceuticals.